Please login to the form below

Not currently logged in
Email:
Password:

emicizumab

This page shows the latest emicizumab news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

However, new drugs including Ocrevus (ocrelizumab) for multiple sclerosis, cancer immunotherapy Tecentriq (atezolizumab) and new haemophilia drug Hemlibra (emicizumab) acted as a buffer.

Latest news

  • Roche gets EU nod for much-expanded Hemlibra label Roche gets EU nod for much-expanded Hemlibra label

    The EU medicines regulator has approved Hemlibra (emicizumab) to prevent or reduce the frequency of bleeding episodes in children and adults with haemophilia A without inhibitors – antibodies that bind to factor

  • Roche buys gene therapy specialist Spark for $4.3bn Roche buys gene therapy specialist Spark for $4.3bn

    Moreover, the deal also gives it multiple gene therapy candidates for haemophilia, a category the company broke into a couple of years ago with its fast-growing Hemlibra (emicizumab) antibody which

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    Roche claimed a positive opinion for Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in adults and children with severe haemophilia A without factor VIII inhibitors, greatly extending the number if

  • Ocrevus helps Roche shrug off biosimilars in 2018 Ocrevus helps Roche shrug off biosimilars in 2018

    New haemophilia drug Hemlibra (emicizumab) added 224m francs, which Schwan said was ahead of expectations – and Esbriet (pirfenidone) for lung disease idiopathic pulmonary fibrosis (IPF) brought in just over 1bn francs,

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    Another bright spot for Roche was strong early uptake of new haemophilia A therapy Hemlibra (emicizumab), a blockbuster-in-waiting which added CHF 113m to the pot from its use in

More from news
Approximately 5 fully matching, plus 22 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics